← Research library

Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application

Patent disclosure · 2006

What the patent describes
Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
Reported evidence
Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.

Reported patent results

Reported findings

The clinical examples describe improvement during adjunctive Bemitil treatment, without group-level efficacy scores or a controlled patient comparison.

Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.

Population or model Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.

Results · Description: Examples 3, 5 and 6; Table 3 and separate clinical group narratives.
MeasureResultComparison, timing and statistics
MS illustrative caseReported clinical/MRI remission, improved strength, coordination, memory, mood and sleepOne 47-year-old patient also receiving piracetam, pentoxifylline and vitamins · After approximately 3 weeks
Chronic-fatigue illustrative caseReported improvement in general condition, tremor, headaches, coordination and perceived weaknessOne 29-year-old patient receiving several other medicines · After a 15-day course
Animal maze experiment216.6 ± 12.1 s with Bemitil versus 304.9 ± 33.3 s after injury alone; uninjured control 224.3 ± 14 s25 mice per group; duration to exploration criterion, not a patient disability score

No aggregate MS relapse, disability-progression or MRI-lesion outcome is supplied for the 10-patient group. Selected adjunctive cases cannot establish disease modification or ME/CFS efficacy.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Use. Bemitil in multiple sclerosis, with a small historical case series and concurrent treatment; not a controlled MS efficacy trial.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2267319C2 ↗ · 2006-01-10
Earliest priority / filing
2003-07-15 / 2003-07-15
Original applicant / assignee
Общество с ограниченной ответственностью "Интер-Кэр"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
35208242 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application

Inventors: Олег Валентинович Дорожко (RU); Олег Валентинович Дорожко; Георгий Иванович Ковалев (RU); Георгий Иванович Ковалев; Рамиз Меджидович Салимов (RU); Рамиз Меджидович Салимов.

RU2267319C2

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
  • The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
  • Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.

Source details

Patent full text

The summary reflects the results reported in the cited source.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

O. V. Dorozhko, G. I. Kovalev, R. M. Salimov. Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards